(Q34284854)

1 August 2017

1 reference

title

Lessons from the glitazones: a story of drug development (English)

1 reference

1 August 2017

E A Gale

1

1 reference

PubMed ID

11410214

1 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

1 August 2017

1 reference

1 August 2017

357

1 reference

1 August 2017

9271

1 reference

1 August 2017

1870-1875

1 reference

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

PPARgamma, the ultimate thrifty gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

1 reference

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

PPARgamma and colorectal carcinoma: conflicts in a nuclear family

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Thiazolidinediones: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Being a modern pharmaceutical company: involves making information available on clinical trial programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

1 reference

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Time to register randomised trials. The case is now unanswerable

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

The glitazones: proceed with caution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

On the need for outcome trials in preventive pharmacology. Lessons from the recent experience with adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904960-6

7 January 2021

10.1016/S0140-6736(00)04960-6

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11410214